1.
Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD
by Donohue, James F
Respiratory medicine, 2016, Vol.116, p.41-48
2.
Pain related readmissions/revisits following same-day surgery: Have they decreased over a decade?
by Herbst, Martha O
Journal of clinical anesthesia, 2017-11, Vol.42, p.15-15
3.
4.
Bleeding Risk Following Percutaneous Coronary Intervention in Patients with Diabetes Prescribed Dual Anti-platelet Therapy
by Grodzinsky, Anna, MD
The American heart journal, 2016, Vol.182, p.111-118
5.
Preclinical Pharmacology and Opioid Combinations
by Pasternak, Gavril W.
Pain medicine (Malden, Mass.), 2012-03, Vol.13 (s1), p.S4-S11
6.
Hepatitis C virus treatment revolution: need for close monitoring
by Ippolito, G
Clinical microbiology and infection, 2014-11, Vol.20 (11), p.O790-O791
7.
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcr...
by Arribas, José R, Dr
The Lancet infectious diseases, 2015, Vol.15 (7), p.785-792
8.
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT...
by Perez-Molina, José A, PhD
The Lancet infectious diseases, 2015, Vol.15 (7), p.775-784
9.
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
by Imai, E
Diabetologia, 2011-10-13, Vol.54 (12), p.2978-2986
10.
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
by Ruslami, Rovina, PhD
The Lancet infectious diseases, 2013, Vol.13 (1), p.27-35
11.
Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
by Lortholary, O
Clinical microbiology and infection, 2011-12, Vol.17 (12), p.1882-1889
12.
Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitan...
by Speich, Benjamin, PhD
The Lancet infectious diseases, 2015, Vol.15 (3), p.277-284
13.
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
by Tak, P P
Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.39-46
14.
Prevention of malaria in pregnancy
by Desai, Meghna
The Lancet infectious diseases, 2018-04, Vol.18 (4), p.e119-e132
15.
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled...
by Sulkowski, Mark, Prof
The Lancet infectious diseases, 2013, Vol.13 (7), p.597-605
16.
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study
by Carey, Dianne
The Lancet infectious diseases, 2015, Vol.15 (7), p.793-802
17.
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid a...
by Verschueren, P
Annals of the rheumatic diseases, 2015-01, Vol.74 (1), p.27-34
18.
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir i...
by Arribas, Jose R, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.581-589
19.
Researchers sound alarm on 'silent' drug interactions
by Hutson, Stu
Nature medicine, 2011-01, Vol.17 (1), p.6-6
20.
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis
by Calzetta, Luigino
Respiratory medicine, 2017-08, Vol.129, p.189-198
